|
|
|
|
|
| Efficacy and mechanism of action of ulinastatin for treatment of systemic inflammatory response syndrome associated with acute severe cerebral hemorrhage |
| Li Jian-guo, Guo Wei, Shan Kai, Xu Bin, Yang Tie-cheng, Dong Xiao-yan, Chen Bi-yao, Du Han-yang, Hao Feng, Mu Hong |
| Department of Emergency, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100050, China |
|
|
|
|
Abstract Objective: To evaluate the clinical efficacy, safety and mechanism of action of ulinastatin for the treatment of systemic inflammatory response syndrome (SIRS) associated with acute severe cerebral hemorrhage. Methods: The patients with acute severe cerebral hemorrhage-associated SIRS were randomized into the treatment group and control group to receive standard of care. Ulinastatin was administered as add-on in the treatment group and the same volume of physiological saline was administered as control in the control group. Serum TNF-α, IL-1 and IL-6 levels were measured before and after treatment. 〖WTHZ〗Results〓〖WTBZ〗 One hundred patients with acute severe cerebral hemorrhage-associated SIRS were randomized into the treatment group (n=50) and control group (n=50). No significant differences in population data were seen between both groups. At Day 1 and Day 7, the ulinastatin treatment group had statistically significantly lower serum levels than the control group ［(9.65±3.72)pg/mL, (6.82±4.64)pg/mL］, IL-1［(5.33±2.36)pg/mL, (3.62±2.56)pg/mL］and IL-6［(11.65±5.67)pg/mL, (8.52±4.85)pg/mL］(P＜0. 05). At Day 7 and Day 28, the treatment group had a statistically significantly lower NIHSS score and incidence of multiple organ dysfunction syndrome (MODS) than the control group ［(14.5±5.2)scores, (12.1±5.4)scores, (40.8%, 66.6%)］, (P＜0.05). 〖WTHZ〗Conclusion〓〖WTBZ〗Ulinastatin effectively reduces the serum TNF-α, IL-1 and IL-6 levels in patients with acute severe cerebral hemorrhage-associated SIRS, thus reducing the incidence of MODS and improving prognosis.
|
|
Received: 25 August 2017
|
|
Corresponding Authors:
Guo Wei, E-mail:guowei1010@126.com
|
|
|
|
| ［1］Davenport RJ, Dennis MS, Wellwood I,et al. Complications after acute stroke［J］. Stroke, 1996, 27(3):415- 420.
［2］Johnston KC, Li JY, Lyden PD, et al.Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial: RANTTAS investigators［J］.Stroke, 1998, 29(2):447-453.
［3］Godoy D, Boccio A, Hugo N. Systemic inflammatory response syndrome and primary of spontaneous intracerebral haemorrhage［J］.Rev Neurol, 2002, 35(12):1101 -1105.
［4］赵性泉,龙洁,郑芳文,等.208例急性脑血管病并发多脏器衰竭死亡病例分析［J］.首都医科大学学报, 2000, 21(2):144-146.
［5］郭洪志, 王蕾, 齐新, 等.脑出血致多器官功能障碍综合征动物模型的建立及其发病机制的研究［J］.中国脑血管病杂志, 2004, 1(10):461-464.
［6］李丽,郭洪志.急性脑出血诱发全身炎症反应综合征致多器官功能障碍综合征的临床研究［J］.中风与神经疾病杂志, 2004, 21(4):362-364.
［7］Dziedzic T, Bartus S, Klimkowicz A, et al. Intracerebral hemorrhage triggers interleukin-6 and interleukin-10 release in blood［J］.Stroke, 2002, 33(9):2334-2335.
［8］Liesz A, Middelhoff M, Zhou W, et al. Comparison of humoral neuroinflammation and adhesion molecule expression in two models of experimental intracerebral hemorrhage［J］. Exp Transl Stroke Med, 2011, 3(1):11-18.
［9］Johnson GB, Brunn GJ, Samstein B, et al. New insight into the pathogenesis of sepsis and the sepsis syndrome［J］.Surgery, 2005, 137(4):393-395.
［10］Kirchhoff C, Biberthaler P, Mutschler WE, et al. Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study［J］.Crit Care, 2009, 13(3):R88.
［11］林洪远, 管向东, 周立新, 等.乌司他丁、α1胸腺肽联合治疗严重脓毒症—一种新的免疫调理治疗方法的临床研究［J］.中华医学杂志, 2007, 87(7):451-457.
［12］施旖旎，黄子通，蒋龙元，等. 乌司他丁治疗全身炎症反应综合征的临床研究［J］.中国急救医学, 2004, 24(10):738-739.
［13］倪红英, 方强, 张云涛, 等.乌司他丁对重症脓毒症患者炎性反应的影响及疗效评价［J］.中国急救医学, 2008, 28(4):342-344.
［14］Wang LZ,Luo MY,Zhang JS, et al.Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis［J］. Int J Clin Pharmacol Ther, 2016, 54(11):890-898.
［15］Liu D,Yu Z,Yin J, et al. Effect of ulinastatin combined with thymosin alpha1 on sepsis: A systematic review and meta-analysis of Chinese and Indian patients［J］. J Crit Care, 2017, 39:258-287.
［16］Zhang C,Wang Y,Fu W, et al. A meta-analysis on the effect of ulinastatin on serum levels of c-reactive protein, interleukin 6, and tumor necrosis factor alpha in asian patients with acute pancreatitis［J］.Genet Test Mol Biomarkers, 2016, 20(3):118-124.
［17］Jia LJ,Yi L,Yang ZX, et al.Preventive effects of ulinastatin on acute respiratory distress syndrome［J］. Beijing Da Xue Xue Bao, 2016, 48(1):672-679.
［18］Wang L,Huang X,Kong G, et al. Ulinastatin attenuates pulmonary endothelial glycocalyx damage and inhibits endothelial heparanase activity in LPS-induced ARDS［J］. Biochem Biophys Res Commun,2016, 478(2):669-675.
［19］Zhou J,Lian J,Li HX, et al.Mechanism research and effect of ulinastatin in the brain tissue injury of acute hydrogen sulfide intoxicated rats［J］. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 2016, 34(3):166-172.
［20］Li X, Su L, Zhang X, et al. Ulinastatin downregulates TLR4 and NF-kB expression and protects mouse brains against ischemia/reperfusion injury［J］.Neurol Res, 2017, 39(4):367-373.
［21］Hui L,Shen F,Chang H, et al. Effects of ulinastatin on cerebral oxygen metabolism and CRP levels in patients with severe traumatic brain injury［J］. Exp Ther Med, 2014, 7(6):1683-1686. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
